Medtronic Gets FDA Clearance For First MRI-Safe CRT-D Devices

Continuing its track record of introducing the first magnetic resonance imaging (MRI)-safe cardiac devices to the market, Medtronic recently gained approval from the U.S. Food and Drug Administration (FDA) for cardiac resynchronization therapy defibrillators (CRT-Ds) for heart failure patients undergoing MRI scans.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news

Related Links:

Publication date: Available online 29 May 2020Source: IDCasesAuthor(s): Anita Singh, Angel Porras, Francisco Ujueta, Saberio Lo Presti, Nicholas Camps
Source: IDCases - Category: Infectious Diseases Source Type: research
Publication date: June 2020Source: IJC Heart &Vasculature, Volume 28Author(s): Donato Mele, Gabriele Pestelli, Davide Dal Molin, Andrea Fiorencis, Filippo Flamigni, Giovanni Andrea Luisi, Vittorio Smarrazzo, Filippo Trevisan, Roberto Ferrari
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
Medtronic is recalling its HeartWare HVAD pump outflow graft and outflow graft strain relief because of the risk of breaks and tears during the pre-implant pump assembly process. FDA has identified this as a Class I recall. The Dublin-based company said it has received 92 complaints. The recalled products according to FDA’s release are: HeartWare HVAD Pump Outflow Graft and Outflow Graft Strain Relief Model Numbers:HVAD Pump Outflow Graft: 1125 HVAD Pump Implant Kit: 1103 HVAD Implant Accessories Kit: 1153 Distribution Dates: March 1, 2018 to April 1, 2020   Medtronic said the use of the affe...
Source: MDDI - Category: Medical Devices Tags: Cardiovascular Regulatory and Compliance Source Type: news
A fair amount of effort is presently put towards the exploration of supplements derived from vitamin B3 compounds (nicotinamide, niacin, nicotinamide riboside) that act as precursors to enable the manufacture of nicotinamide adenine dinucleotide (NAD). NAD is an important component in mitochondrial activity, and levels decline with age. Some portion of the loss of mitochondrial function, implicated in the progression of many age-related conditions, is due to NAD insufficiency. There is a rich history of the use of high doses of vitamin B3 as an intervention, most of it predating modern understanding of the role of NAD in m...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
(European Society of Cardiology) Save the date for HFA Discoveries, the latest scientific platform of the European Society of Cardiology (ESC). Find out what's on the horizon for prevention and treatment during this innovative online event.Worldwide, an estimated 26 million people have heart failure.1 In Europe, one-year all-cause mortality rates for acute and chronic heart failure are 23.6% and 6.4%, respectively, and heart failure hospitalisation rates are 18.7% and 9.9%, respectively.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
(University of Arkansas) With funding from the National Institutes of Health, University of Arkansas researchers hope to develop the first therapeutic drug to regenerate heart tissue. The lesion-seeking drug, released through stent placement, could treat coronary blockages and prevent heart failure.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 28 May 2020Source: Preventive MedicineAuthor(s): Corinna A. Noel, Michael J. LaMonte, Mary B. Roberts, Deborah H. Pearlman, Hailey Banack, Matthew Allison, Aladdin H. Shadyab, Bernhard Haring, Deepika Laddu, Lisa Warsinger Martin, Patricia K. Nguyen, JoAnn E. Manson, Charles B. Eaton
Source: Preventive Medicine - Category: International Medicine & Public Health Source Type: research
ConclusionsEvidence of MR in retrospective claims significantly increases the clinical burden of incident HF patients. Time to death and CV hospitalizations are increased when MR is clinically significant.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
This study aimed to investigate the role of testosterone in predicting major adverse cardiac events in the Chinese AR VC cohort.Methods and resultsNinety ‐nine ARVC patients (median age, 40 years; 70.7% male) and 96 healthy controls (median age, 41 years; 62.5% male) were enrolled. The circulating levels of testosterone were measured by enzyme‐linked immunosorbent assays (ELISA). The median follow‐up time of all ARVC male patients was 17 mon ths (interquartile range/IQR 9–29). Cox proportional hazards regression was used to analyse the effect of plasma testosterone and other well‐described risk...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Position Paper Source Type: research
More News: Cardiac Resynchronization Therapy | Cardiology | Food and Drug Administration (FDA) | Heart | Heart Failure | Medical Devices | MRI Scan | PET Scan